<DOC>
	<DOCNO>NCT01617317</DOCNO>
	<brief_summary>Treatment hyperimmune intravenous immunoglobulin ( H-IVIG ) , derive convalescent plasma patient recover H1N1 2009 influenza A infection , patient severe H1N1 2009 infection decrease mortality , reduce viral load , shorten length stay ICU hospital .</brief_summary>
	<brief_title>H-IVIG Treatment Severe H1N1 2009</brief_title>
	<detailed_description>Since emergence novel swine origin influenza A virus ( H1N1 2009 ) Mexico March 2009 , virus lead pandemic 170 country , result 180 thousand microbiologically confirm case 18000 mortality . This strain represent quadruple re-assortment two swine strain , one human strain , one avian strain influenza . Although H1N1 2009 cause mild disease relatively low mortality rate currently Hong Kong , severe case report . Patients infect severe H1N1 2009 overwhelm intensive care service country mortality rise 6 % Argentina Brazil , 0.4 % Australia . This much high 0.06 % mortality rate seasonal flu . Furthermore , report H1N1 2009 oseltamivir resistance zanamivir difficult deliver consolidated lung severe case drug need . In Hong Kong , vaccination H1N1 2009 prioritise old people age 65 chronic illness , young people chronic illness health care worker . The healthy adult age 18 65 , risk develop severe H1N1 2009 cover vaccination program . Experience 1918 H1N1 pandemic single case report treatment severe H5N1 infection ( Zhou et al . 2007 ) show hyperimmune convalescent plasma useful ( Luke et al . 2006 ) . Mice experiment also show antibody therapy highly effective case H5N1 infection ( Heltzer ML et al . 2009 , Writing Committee Second World Heath Organization , 2008 ) . Therefore , convalescent plasma patient recover H1N1 2009 infection harvest prepare hyperimmune intravenous immunoglobulin ( H-IVIG ) prepare H-IVIG assess randomise controlled trial treatment patient severe H1N1 2009 infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>( fulfill criterion ) : male female patient 18 year old write informed consent patient next kin ( patient ill ) diagnosis H1N1 2009 infection satisfy clinical laboratory criterion : 1 . Laboratory criterion : least one RTPCR positive H1N1 2009 one clinical specimen ( NPA , ETA , blood , urine stool ) . 2 . Clinical criterion : patient admit ICU severe community acquire pneumonia define CURB65 score 3 deterioration treatment optimal antiviral ( oral inhaler agent ) typical atypical antimicrobial coverage require ICU ventilatory support within 7 day onset symptom . age 18 year know hypersensitivity immune globulin component formulation know IgA deficiency acquire H1N1 2009 infection health care facility moribund patient refusal informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>H1N1 2009</keyword>
	<keyword>hyperimmune IVIG</keyword>
	<keyword>mortality</keyword>
	<keyword>length stay</keyword>
	<keyword>viral load</keyword>
	<keyword>cytokine</keyword>
</DOC>